MyFinsight
Home
Blog
About
Contact
Download
Download image
Issuance of common stock
from equity...
$793K
Issuance of common stock
from employee stock...
$672K
Net cash provided by
financing activities
$1,465K
Net decrease in
cash, cash...
-$15,574K
Canceled cashflow
$1,465K
Deferred revenue
$10,711K
Stock-based compensation
expense
$5,068K
Non-cash interest
expense and...
$4,432K
Foreign currency
exchange loss (gain)
-$1,687K
Fair value
adjustment to derivative...
-$1,605K
Depreciation and
amortization
$355K
Non-cash operating lease
expense
$158K
Realized loss (gain) from
sale of marketable...
-$11K
Sales and maturities
of marketable...
$15,730K
Net cash used in
operating activities
-$14,455K
Effect of exchange rate
changes
-$1,683K
Canceled cashflow
$24,027K
Net cash used in
investing activities
-$901K
Canceled cashflow
$15,730K
Net loss
-$23,487K
Accounts receivable, net
$7,322K
Accrued expenses and
other liabilities
-$5,220K
Research and development
tax credit...
$1,355K
Inventory
$665K
Prepaid expenses and
other assets
$184K
Accounts payable
-$149K
Accretion of discount on
marketable securities
-$100K
Purchases of marketable
securities
$16,428K
Commercial
-$37,707K
Total revenues
$27,171K
Research
-$24,479K
Other sg&a
-$21,811K
Clinical development
-$16,866K
Regulatory & qa
-$5,126K
Acquisition of property and
equipment
$121K
Capitalized website
development costs
$82K
Segment net loss
-$23,487K
Canceled cashflow
$133,160K
something is missing
-$153,365K
Cost of revenue
$1,858K
Other (expense)
income
-$1,424K
Back
Back
Cash Flow
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)
source: myfinsight.com